ZIM
CASC

Zacks Investment Management’s Cascadian Therapeutics, Inc. CASC Stock Holding History

Zacks Investment Management’s Portfolio CASC Stock Details CASC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-16,424
Closed -$161K – 774
2015
Q1 		$161K Buy
+16,424
New +$161K 0.01% 606

Other funds holding CASC

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Zacks Investment Management's CASC Position: Q2 2015 in Review

Zacks Investment Management sold out of Cascadian Therapeutics, Inc. (CASC) in Q2 2015, closing a stake of 16,424 shares — an estimated $161K sold.

Zacks Investment Management first reported a position in CASC in Q1 2015 and held it in 1 quarter. The position peaked at $161K in Q1 2015. 100 funds tracked by Wall St. Rank hold CASC as of Q2 2015.

  • Zacks Investment Management reported no remaining Cascadian Therapeutics, Inc. position as of Q2 2015 after selling out during the quarter.
  • Zacks Investment Management sold 16,424 Cascadian Therapeutics, Inc. shares in Q2 2015, an estimated $161K.
  • Zacks Investment Management first reported a position in Cascadian Therapeutics, Inc. in Q1 2015 and held it in 1 quarter.
  • Zacks Investment Management's Cascadian Therapeutics, Inc. position peaked at $161K in Q1 2015.
  • 100 funds tracked by Wall St. Rank held Cascadian Therapeutics, Inc. as of Q2 2015.

Based on Zacks Investment Management's 13F filing for Q2 2015, filed 12 Aug 2015.